BioNTech SE (BNTX)

Healthcare · Biotechnology
$96.50 +0.80% on the day Market cap $24.4B 52-week range $79.52 to $124.00 Prices as of Oct 7, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

BioNTech SE's free cash flow isn't comparable to its market value here, so a cash-flow reverse DCF doesn't give a meaningful answer. The Modeling tab works from revenue and margins instead.

Fundamental grade

D

Five factors scored 1 to 9 from BNTX's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation5
Profitability2
Growth3
Financial health9
Cash efficiency4

Key numbers

P/E (trailing)—
P/E (forward)7.36x
Price / free cash flow—
EV / EBITDA32.7x
Price / sales8.69x
Price / book1.08x
Revenue growth+4.3%
Operating margin-49.0%
Net margin-39.6%
Return on equity-5.9%
Dividend yield—
Debt / equity0.14x

Results from SEC filings

Fiscal years, from BioNTech SE's 10-K filings. The deep dive has 15+ years, quarters and every line.

Fiscal year20212022202320242025
Revenue$19.0B$17.3B$3.8B$2.8B$2.9B
Net income$10.3B$9.4B$930M-$665M-$1.1B
Free cash flow$762M$13.2B$5.1B-$79M$281M
EPS (diluted)$39.63$37.77$3.83-$2.77-$4.70
Operating margin80.5%73.0%18.1%-47.8%-49.0%

Where the revenue comes from

Revenue by products, fiscal 2025.

COVID-19 vaccine revenues$2.0B70%
Revenues from out-licensing$613M21%
Other revenues$262M9%

Superinvestors who own BNTX

From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
PRIMECAP Management
PRIMECAP Management Co
Trimmed $351M0.21%Q2 2026
Dodge & Cox
Dodge & Cox
Added $342M0.18%Q2 2026
Ron Baron
Baron Capital (BAMCO)
Held $72,2070.0%Q2 2026

Insider buying

Open-market purchases by BioNTech SE's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of BNTX in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when BNTX trades at or below it.

$

Free accounts get 3 price alerts. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

Are BioNTech SE insiders buying the stock?

No open-market insider purchases of BNTX in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own BioNTech SE?

3 of the superinvestors Investingly tracks hold BNTX in their latest 13F, including PRIMECAP Management, Dodge & Cox, Ron Baron.

Prices and ratios as of Oct 7, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.